Results 211 to 220 of about 196,164 (338)

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia [PDF]

, 2012
K. H. Bauer, Michaela Rancea, Verena Roloff, Thomas Elter, Michael Hallek, Andreas Engert, Nicole Skoetz   +6 more
openalex   +1 more source

Practical Approach to Managing SCIg Treatment in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Guidelines for the management of chronic inflammatory demyelinating polyneuropathy (CIDP) recommend corticosteroids, intravenous immunoglobulin (IVIg), or plasma exchange for first‐line therapies and subcutaneous immunoglobulin (SCIg) as a maintenance option.
Tuan Vu, Claudia Guerra, Niraja Suresh, Sami Khella, Jamie Morrell, Michael Pulley, Nan Jiang, Khema Sharma, Tulio Bertorini, Nivedita Jerath, Amanda Peltier   +10 more
wiley   +1 more source

Persistent COVID-19 Pneumonia in a Patient on Rituximab. [PDF]

J Investig Med High Impact Case Rep
Clarke K, Naidu S, Wan C, Stampfer S.
europepmc   +1 more source

Hepatitis B Reactivation and Rituximab in the Oncology Practice [PDF]

, 2010
Jeryl Villadolid, Kourtney D. LaPlant, Merry Jennifer Markham, David R. Nelson, Thomas J. George   +4 more
openalex   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report. [PDF]

Clin Case Rep
Sahebari M, Karimoddini M, Tayyebi Meibodi N, Ataei Azimi S, Tafreshian S.   +4 more
europepmc   +1 more source

Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.

, 2015
Bo Jia, Yuankai Shi, Suyi Kang, Sheng Yang, Shaoxuan Hu, Ye‐Xiong Li, Mei Dong, Weihu Wang, Jianliang Yang, Liqiang Zhou, Peng Liu, Shengyu Zhou, Yan Qin, Lin Gui, Changgong Zhang, Hua Lin, Shanshan Chen, Lin Wang, Xiaohui He   +18 more
openalex   +2 more sources

Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma [PDF]

, 2015
Tiansuo Zhao, He Ren, Xiuchao Wang, Pengfei Liu, Yan Fan, Wenna Jiang, Yang Li, Jing Li, John G. Gribben, Li Jia, Jihui Hao   +10 more
openalex   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Rituximab maintenance after autologous stem‐cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group [PDF]

, 2017
Steven Le Gouill, Catherine Thiéblemont, Lucie Obéric, Anne‐Sophie Moreau, Krimo Bouabdallah, C. Dartigeas, Ghandi Damaj, Thomas Gastinne, Vincent Ribrag, Pierre Feugier, Olivier Casasnovas, Hacène Zerazhi, Corinne Haïoun, Hervé Maisonneuve, Éric Van Den Neste, Olivier Tournilhac, Katell Le Dû, Franck Morschhauser, Guillaume Cartron, Luc Mathieu Fornecker, Gilles Salles, Hervé Tilly, T. Lamy, Rémy Gressin, Olivier Hermine   +24 more
openalex   +1 more source